Hepatitis C screening: Getting it right

Hepatology

Volumn 57, Issue 4, 2013, Pages 1644-1650

  Edlin, Brian R ^a,b  

^a NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN;

ANTIVIRAL THERAPY; ARTICLE; ASYMPTOMATIC INFECTION; DECISION MAKING; GENOTYPE; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SCREENING; VIREMIA;

ADVISORY COMMITTEES; EVIDENCE-BASED MEDICINE; HEALTH PLANNING GUIDELINES; HEPATITIS C; HUMANS; MASS SCREENING; PREVENTIVE HEALTH SERVICES; UNITED STATES;

EID: 84876117364     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26194     Document Type: Article

References (61)

1. Institute of Medicine (ed.). Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. Washington, DC: National Academies Press; 2010.
2. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271-278.
3. U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: recommendation statement. Ann Intern Med 2004; 140: 462-464.
4. Alter MJ, Seeff LB, Bacon BR, Thomas DL, Rigsby MO, Di Bisceglie AM. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med 2004; 141: 715-717.
5. National Institutes of Health. Management of hepatitis C: 2002. NIH Consens State Sci Statements 2002 Jun 10-12;19:1-46. Accessed at: http://consensus.nih.gov/2002/2002HepatitisC2002116html.htm on 11 June 2012.
6. National Institute of Diabetes and Digestive and Kidney Diseases. Chronic Hepatitis C: Current Disease Management. NIH Publication No. 03-4230. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 2003.
7. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998; 47: 1-39.
8. Wright TL, Yee H. VA Treatment Recommendations (Version 5.0). Patients with chronic hepatitis C. Federal Practitioner 2003; 20: 1-33.
9. Strader DB, Wright T, Thomas DL, Seeff LB. AASLD Practice Guideline: diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004; 39: 1147-1171.
10. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130: 225-230.
11. Calonge N, Randhawa G. The meaning of the U.S. Preventive Services Task Force grade I recommendation: screening for hepatitis C virus infection. Ann Intern Med 2004; 141: 718-719.
12. U.S. Preventive Services Task Force. Screening for Hepatitis C Virus Infection in Adults: Draft Recommendation Statement. AHRQ Publication No. 12-05174-EF-2. 26 November 2012. Accessed at: http://www.uspreventiveservicestaskforce.org/draftrec2.htm on 27 November 2012.
13. Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156: 263-270.
14. Edlin BR. Perspective: test and treat this silent killer. Nature 2011; 474: S18-S19.
15. Edlin BR. Five million Americans infected with the hepatitis C virus: a corrected estimate. HEPATOLOGY 2005; 42( 4 Suppl 1): 213A.
16. Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol 2010; 8: 1017-1029.
17. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313.
18. McHutchison JG, Ware JE, Jr., Bayliss MS, Pianko S, Albrecht JK, Cort S, et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34: 140-147.
19. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
20. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
21. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139: 1593-1601.
22. Butt AA, Wang X, Moore CG. Effect of hepatitis C virus and its treatment on survival. HEPATOLOGY 2009; 50: 387-392.
23. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 509-516 e1.
24. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011; 52: 889-900.
25. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8: 280-288.
26. Ng V, Saab S. Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 923-930.
27. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2010; 8: 192-199.
28. Chung RT. A watershed moment in the treatment of hepatitis C. N Engl J Med 2012; 366: 273-275.
29. Alter HJ, Liang TJ. Hepatitis C: the end of the beginning and possibly the beginning of the end. Ann Intern Med 2012; 156: 317-318.
30. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 2001; 20( 3 Suppl): 21-35.
31. Chou R. Routine screening for chronic human immunodeficiency virus infection: why don't the guidelines agree? Epidemiol Rev 2011; 33: 7-19.
32. Guirguis-Blake J, Calonge N, Miller T, Siu A, Teutsch S, Whitlock E. Current processes of the U.S. Preventive Services Task Force: refining evidence-based recommendation development. Ann Intern Med 2007; 147: 117-122.
33. U.S. Preventive Services Task Force. Section 5: Methods for Arriving at a Recommendation. In: Procedure Manual. AHRQ Publication No. 08-05118-EF: Agency for Healthcare Research and Quality; 2008: 44-55. Accessed at: http://www.uspreventiveservicestaskforce.org/uspstf08/methods/procmanual5.htm on 22 March 2012.
34. Trepka MJ, Zhang G, Leguen F, Obiaja K, Malow RM, De La Rosa M. Benefits and adverse effects of hepatitis C screening: early results of a screening program. J Public Health Manag Pract 2007; 13: 263-269.
35. Neumann PJ, Cohen JT, Hammitt JK, Concannon TW, Auerbach HR, Fang C, et al. Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Econ 2012; 21: 238-251.
36. Coffin PO, Stevens AM, Scott JD, Stekler JD, Golden MR. Patient acceptance of universal screening for hepatitis C virus infection. BMC Infect Dis 2011; 11: 160.
37. U.S. Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: recommendation statement. Ann Intern Med 2004; 140: 554-556.
38. Chou R, Cottrell EB, Wasson N, Rahman B, Guise J-M. Screening for Hepatitis C Virus Infection in Adults. Comparative Effectiveness Review No. 69. AHRQ Publication No. 12(13)-MEHC090-MEF. Rockville, MD: Agency for Healthcare Research and Quality; 2012.
39. Kimer N, Dahl EK, Gluud LL, Krag A. Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. BMJ Open 2012; 2: e001313.
40. Kanwal F, Schnitzler MS, Bacon BR, Hoang T, Buchanan PM, Asch SM. Quality of care in patients with chronic hepatitis C virus infection: a cohort study. Ann Intern Med 2010; 153: 231-239.
41. Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011; 364: 2199-2207.
42. Grebely J, Petoumenos K, Matthews GV, Haber P, Marks P, Lloyd AR, et al. Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study. Drug Alcohol Depend 2009.
43. Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56: 385-389.
44. Rousseau CM, Ioannou GN, Todd-Stenberg JA, Sloan KL, Larson MF, Forsberg CW, et al. Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study. Am J Public Health 2008; 98: 846-852.
45. Davila JA, El-Serag HB. Racial differences in survival of hepatocellular carcinoma in the United States: a population-based study. Clin Gastroenterol Hepatol 2006; 4: 104-110.
46. Siegel AB, McBride RB, El-Serag HB, Hershman DL, Brown RS Jr, Renz JF, et al. Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol 2008; 103: 120-127.
47. Sonnenday CJ, Dimick JB, Schulick RD, Choti MA. Racial and geographic disparities in the utilization of surgical therapy for hepatocellular carcinoma. J Gastrointest Surg 2007; 11: 1636-1646.
48. Sawaya GF, Guirguis-Blake J, LeFevre M, Harris R, Petitti D. Update on the methods of the U.S. Preventive Services Task Force: estimating certainty and magnitude of net benefit. Ann Intern Med 2007; 147: 871-875.
49. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714.
50. Perz JF, Grytdal S, Beck S, Fireteanu AM, Poissant T, Rizzo E, et al. Case-control study of hepatitis B and hepatitis C in older adults: Do healthcare exposures contribute to burden of new infections? HEPATOLOGY 2012 [Epub ahead of print].
51. U.S. Preventive Services Task Force. Screening for HIV: Draft Recommendation Statement. AHRQ Publication No. 12-05173-EF-3. 19 November 2012. Accessed at: http://www.uspreventiveservicestaskforce.org/draftrec.htm on 27 November 2012.
52. McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, et al. Economic model of a birth cohort screening program for hepatitis C virus. HEPATOLOGY 2012; 55: 1344-1355.
53. Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis 2012; 54: 1259-1271.
54. U.S. Preventive Services Task Force. Screening for illicit drug use: recommendation statement. AHRQ Publication Number 08-05108-EF-3. Rockville, MD: Agency for Healthcare Research and Quality; 2008.
55. Woloshin S, Schwartz LM, Black WC, Kramer BS. Cancer screening campaigns-getting past uninformative persuasion. N Engl J Med 2012; 367: 1677-1679.
56. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157: 120-134.
57. Petitti DB, Calonge N, LeFevre ML, Melnyk BM, Wilt TJ, Schwartz JS. Breast cancer screening: from science to recommendation. Radiology 2010; 256: 8-14.
58. Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001; 345: 211-214.
59. Edlin BR, Carden MR. Injection drug users: the overlooked core of the hepatitis C epidemic. Clin Infect Dis 2006; 42: 673-676.
60. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 2011; 43: 66-72.
61. Smith BD, Morgan RL, Beckett GA, Falck_Ytter Y, Holtzman D, Teo CG, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61: 1-32.